NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

ski, it might be a good idea to take the time to read the published study by the Flaskworks’ technical team, and peruse their patents to inform your speculations. I’ve already replied to you in another post that in both the published study, and in the patents, the Flaskworks’ system was placed in a conventional incubator on a bench top during the maturation process to control temperature and CO2 levels. I’m not sure if this is the currently designed system though, and while I don’t ever recall reading anything about the system being stackable, perhaps it could be. However, it’s completely unnecessary and makes no sense to stack them, so most often the simplest and proven solution is the one that is used. In my opinion, the point is irrelevant, so speculate away.

Northwest Biotherapeutics has an ancillary services agreement with Advent Bioservices to oversee the construction and development of the Sawston manufacturing facility, which includes testing the Flaskworks system and developing an automated process. Milestones in the Flaskworks Purchase Agreement require that the Flaskworks’ technical team assist Advent Bioservices for the deployment and comparability studies of the Flaskworks’ system, as well as the preparation of the necessary documentation for submission to the regulatory agencies in the UK, US, Canada and EU. Nowhere in this agreement does it state that Cognate, Charles Rivers Labs, or UCLA will be conducting any validation activities with the Flaskworks’ system, and I’m not sure why so many posters on this board continue to perpetuate this notion.